Company Overview of CareDx, Inc
CareDx, Inc, a commercial stage company, develops, markets, and delivers diagnostic surveillance solutions for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient’s lifetime. Its commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a blood-based test used to monitor heart transplant recipients for acute cellular rejection. The company markets its AlloMap solution to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators, and nurse practitioners in the United States, Canada, and Europe. The company was formerly known as XDx...
3260 Bayshore Boulevard
Brisbane, CA 94005
Founded in 1998
Key Executives for CareDx, Inc
Chief Executive Officer, President and Director
Total Annual Compensation: $547.6K
Chief Medical Officer and Executive Vice President
Total Annual Compensation: $524.5K
Chief Compliance Officer and Chief Business Officer
Total Annual Compensation: $445.5K
Compensation as of Fiscal Year 2014.
CareDx, Inc Key Developments
CareDx, Inc Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended March 31, 2015; Confirms Revenue Guidance for the Year 2015
Aug 10 15
CareDx Inc. reported unaudited earnings results for the second quarter and six months ended March 31, 2015. For the quarter, the company reported total revenues of USD 7.129 million compared to USD 6.776 million a year ago. Loss from operations was USD 2.886 million compared to USD 0.345 million a year ago. Loss before income taxes was USD 3.185 million compared to USD 0.623 million a year ago. Net loss was USD 3.185 million compared to net income of USD 0.877 million a year ago. Diluted loss per share was USD 0.27 compared to earnings per share of USD 0.13 a year ago.
For the six months, the company reported total revenues of USD 14.344 million compared to USD 12.700 million a year ago. Loss from operations was USD 4.277 million compared to USD 0.572 million a year ago. Loss before income taxes was USD 5.457 million compared to USD 1.927 million a year ago. Net loss was USD 5.457 million compared to USD 0.427 million a year ago. Diluted loss per share was USD 0.46 compared to USD 0.42 a year ago.
The company confirmed revenue for the full year of 2015 is expected to be in the range of USD 28 to USD 30 million.
CareDx Seeks Acquisitions
Aug 10 15
CareDx, Inc (NasdaqGM:CDNA) has filed a Shelf Registration in the amount of $75 million. CareDx will use the net proceeds from the sale of securities offered by this prospectus for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies or businesses.
CareDx, Inc to Report Q2, 2015 Results on Aug 10, 2015
Jul 27 15
CareDx, Inc announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 10, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
January 30, 2015